A permanent J-code did in one quarter what a full year of sales force investment couldn’t: ZUSDURI revenue hit $29.2 million in Q1 2026, a 109% jump from Q4 2025, confirming that reimbursement friction — not clinical hesitancy — was the primary brake on adoption. That distinction matters enormously for how UroGen should be valued. A drug stalled by physician skepticism is a different animal than one stalled by billing ambiguity. The J-code for J9282 became effective January 1, and the revenue response was immediate.
The commercial infrastructure numbers tell a more cautious story beneath the headline. As of March 31, UroGen had 972 activated sites of care but only 256 unique prescribers — and just 103 of those have written a repeat prescription. That’s a 40% repeat-prescriber rate among those who’ve tried the drug at all, which is respectable early in a launch but also means the majority of trialists haven’t yet committed to integrating ZUSDURI into routine practice. The AUA KOL panel on May 17 is clearly designed to accelerate that conversion, leaning on the ENVISION 24-month data showing a 72.2% probability of remaining event-free among complete responders. Real-world durability, not CR rate alone, is what converts a urologist from curious to habitual.
The pipeline layering is strategically aggressive. UGN-103 — a next-generation mitomycin with simplified reconstitution and a 77.8% three-month CR rate from UTOPIA — is on track for NDA submission in H2 2026. This creates an unusual dynamic: UroGen is actively building a successor to a product it launched less than 18 months ago. The logic is portfolio protection rather than cannibalization; a smoother reconstitution process reduces the procedural burden that community urologists cite as a friction point. Meanwhile, the $200 million Pharmakon debt refinancing at a fixed 8.25% with repayment deferred to 2030 buys runway without dilution — a deliberate choice that signals management expects ZUSDURI and JELMYTO cash flows to service that debt comfortably before the balloon comes due.
The single number worth tracking through mid-2026 is the repeat-prescriber count. If that 103 figure doesn’t accelerate sharply by Q2, it signals the J-code unlocked a bolus of pent-up demand rather than a durable prescribing habit — and the blockbuster thesis deflates accordingly.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
